Biotechnology
Harbour BioMed Announces IND Approval for Next-Gen Anti-TSLP Fully Human Monoclonal Antibody
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Feb. 21, 2022 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) announced that China National Medical Products Administration (NMPA) had approved its investigational new drug (IND) application for HBM9378 (or SKB378 as referred to ...
2022-02-21 20:29
2401
Biosion, Inc. Appoints Joel Edwards, MBA, as Chief Business Officer
NEWARK, Del. and NANJING, China, Feb. 21, 2022 /PRNewswire/ -- Biosion, Inc. ("Biosion"), a global clinical stage biotechnology company, today announced the appointment ofJoel Edwards as chief business officer. In this position, he is responsible for strategic leadership over all aspects of the c...
2022-02-21 13:00
1881
OliPass Announces Commencement of Dosing in Phase 2a Trial for Pain Killer OLP-1002
SEOUL, South Korea, Feb. 18, 2022 /PRNewswire/ -- OliPass Corporation, a South Korea based biotech specialized in the development of RNA therapeutics, announced that the dosing of pain killer OLP-1002 commenced for a Phase 2a trial in osteoarthritis patients with pain. The Phase 2a study was appr...
2022-02-18 23:00
3339
Keymed Bio Joins Hang Seng Family of Indexes
HONG KONG, Feb. 18, 2022 /PRNewswire/ -- According to the quarterly review results of Hang Seng Family of Indexes, Keymed Biosciences Inc. (2162. HK) was included a constituent stock of: * Hang Seng Composite Index; * Hang Seng Small Cap (Investable) Index; * Hang Seng Stock Connect Hong K...
2022-02-18 22:10
6757
PolyActiva Announces Positive Phase IIa Trial Results in Low Dose Cohort for PA5108 Ocular Implant with Prezia™ Sustained Drug Delivery Technology
- Primary and Secondary Efficacy Endpoints Met, Demonstrating Statistically - Significant Reduction in Intra-Ocular Pressure (IOP) for Patients with Glaucoma MELBOURNE, Australia, Feb. 18, 2022 /PRNewswire/ -- PolyActiva Pty Ltd, a clinical-stage Australian biopharmaceutical company focused on ...
2022-02-18 08:19
1882
Gracell Biotechnologies Doses First Patients in First-in-Human Clinical Trial Evaluating GC012F, its Dual-Targeting FasTCAR-T Therapy, in B-Cell Non-Hodgkin's Lymphoma
SUZHOU, China and PALO ALTO, Calif., Feb. 17, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today...
2022-02-17 21:30
2759
Flat Medical joins the Stay Connected(R), the International Organization for Safer Neuraxial Anesthesia
TAIPEI, Feb. 17, 2022 /PRNewswire/ -- Flat Medical Co., Ltd., a MedTech company specializing in safety solutions for anesthesia and critical care procedures, has announced that it has just joined the Stay Connected®, a joint communication initiative on behalf of the industry to advocate and educa...
2022-02-17 21:00
1782
PharmaBlock Appoints Dr. Zhengtian Gu as Senior Vice President of Quality and Regulatory Affairs
NANJING, China, Feb. 16, 2022 /PRNewswire/ -- PharmaBlock (300725.SZSE), an innovative chemistry products and services provider to support drug discovery, development, and commercialization, announces the appointment of Dr. Zhengtian (Titan) Gu as Senior Vice President of Quality and Regulatory A...
2022-02-16 20:00
1816
Travecta Therapeutics Appoints Leading Experts to Expand its Scientific Advisory Leadership Team
PRINCETON, N.J. and SINGAPORE, Feb. 15, 2022 /PRNewswire/ -- Travecta Therapeutics, Pte Ltd., a preclinical stage biopharmaceutical company pioneering a portfolio of product candidates engineered to cross the blood-brain-barrier, today announced significant expansion of the Scientific Advisory B...
2022-02-15 21:00
1760
HPG: New Breakthrough in Virus Inactivation with Green Tea Catechin (EGCg)
TOKYO, Feb. 15, 2022 /PRNewswire/ -- HPG Co., Ltd. (Chuo-ku, Tokyo) has successfully developed a water-soluble formulation technology of highly concentrated catechin EGCg (Epigallocatechin gallate) with excellent storage stability and initiated procedures for a patent application for the technolo...
2022-02-15 16:00
1630
Kintor Pharma Announces First Patient Dosing in China in Phase III Clinical Trial of Proxalutamide for the Treatment of COVID-19 Outpatients
SUZHOU, China, Feb. 11, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma," HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced the enrollment and dosing of first patient inChina in its multi-regi...
2022-02-11 20:40
4534
WuXi STA Wins 2022 CMO Leadership Awards in All Six Core Categories
SHANGHAI, Feb. 10, 2022 /PRNewswire/ -- WuXi STA, a subsidiary of WuXi AppTec, today announced that it received 2022 CMO Leadership Awards in all six core categories including Capabilities, Compatibility, Expertise, Quality, Reliability and Service and scored as a 2022 CMO Leadership Award Champi...
2022-02-11 10:00
2188
Ucello Therapeutics Completes US$25 Million Series A Financing
SAN DIEGO, Calif. and CHENGDU, China, Feb. 10, 2022 /PRNewswire/ -- Ucello Therapeutics ("Ucello"), a biotechnology company developing universal CAR-T therapies, announced the successful completion of aUS$25 million Series A financing. The funding round was led by Matrix Partners China, alon...
2022-02-11 02:16
2357
AKESO'S NGF MONOCLONAL ANTIBODY (AK115) APPROVED TO INITIATE CLINICAL TRIAL IN PAIN (INCLUDING CANCER PAIN)
HONG KONG, Feb. 10, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced that the clinical trial application of the innovative nerve growth factor (NGF) monoclonal antibody (research and development code: AK115) injection developed in-house by the Company, has obtained approval from the Centre fo...
2022-02-10 17:00
2402
Prota Therapeutics Achieves Peanut Allergy Treatment Milestone: Groundbreaking Clinical Trial Data Demonstrates Clinical Remission of Peanut Allergy in Paediatric Patients
* Groundbreaking New Clinical Trial Data Published in The Lancet Child & Adolescent Health * Data shows that 51% of participants achieved sustained unresponsiveness (clinical remission) to peanut after 18 months of treatment * Prota Therapeutics announces new round of capital raising for fur...
2022-02-09 20:00
1738
Sirnaomics Launches Phase I Clinical Trial of RNAi Therapeutic STP707 Delivered Systemically for the Treatment of Solid Tumors
HONG KONG, Feb. 9, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced the start of a Phase I clinical trial for evaluation of the safety, tolerability and anti-...
2022-02-09 17:12
2001
Bridge Biotherapeutics and Scripps Research Launch Research Collaboration to Develop Discovery Platform and Novel Covalent Probes Based on Chemical Biology and Chemoproteomics
* Two-year research collaboration to develop new reactive group chemistries targeting non-cysteine amino acids to expand druggable binding sites and identify novel targets in oncology and immunology * Collaborators at Scripps are pioneers in the field of chemical biology and chemistry SEONGNA...
2022-02-08 06:00
2126
IonOpticks enters OEM partnership with Bruker that sets a new standard for mass spectrometry-based research
MELBOURNE, Australia, Feb. 7, 2022 /PRNewswire/ -- Premium manufacturer of chromatography for proteomics applications, IonOpticks, has entered an OEM partnership with the Bruker Corporation (Nasdaq: BRKR), allowing Bruker to expand their portfolio of 4D-Proteomics solutions with the release of th...
2022-02-08 00:01
2330
Samsung Biologics receives 2022 CMO Leadership Award in all six categories
INCHEON, South Korea, Feb. 7, 2022 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), the world's leading contract development and manufacturing organization (CDMO), announced that it has been selected as a winner of the 2022 CMO Leadership Awards presented by Outsourced Pharma and Life Science ...
2022-02-07 20:00
2451
Laekna Launched the new domain name www.laekna.com
SHANGHAI and WARREN, N.J., Feb. 6, 2022 /PRNewswire/ -- Laekna Group (Laekna Inc and all its direct or indirect subsidiaries, including Laekna Therapeutics Shanghai Co., Ltd.), an emerging innovative biotech based inChina's "Zhangjiang Pharma Valley" andNew Jersey in the U.S. and focused on devel...
2022-02-07 12:47
1732
Week's Top Stories
Most Reposted
Radisson Hotel Group accelerates growth in Indonesia with ANTA Hotel Bali Canggu, a member of Radisson Individuals
[Picked up by 313 media titles]
2025-12-10 10:00
HKSTP Makes Strategic Investment in Singapore Technology Company Vizzio; Forges Innovation Pact to Power Next-Generation AI and Smart City
[Picked up by 306 media titles]
2025-12-09 13:31
ARKANCE to Launch BIMLOGIQ - A New AI-Powered Extension to Its AEC Tech Stack Offering
[Picked up by 293 media titles]
2025-12-11 09:07
BeLive Studios, NewUnivers and ChopChop Systems Sign Memorandum of Understanding at ATF 2025
[Picked up by 288 media titles]
2025-12-08 11:00
Tiiny AI Reveals World's Smallest Personal AI Supercomputer, Verified by Guinness World Records
[Picked up by 285 media titles]
2025-12-10 16:00
